STOCK TITAN

Aytu BioPharma Inc - AYTU STOCK NEWS

Welcome to our dedicated news page for Aytu BioPharma (Ticker: AYTU), a resource for investors and traders seeking the latest updates and insights on Aytu BioPharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aytu BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aytu BioPharma's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.76%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.78%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.57%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.18%
Tags
covid-19
Aytu BioPharma Inc

NASDAQ:AYTU

AYTU Rankings

AYTU Stock Data

15.92M
3.80M
3.49%
31.78%
6.48%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Loveland

About AYTU

aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.